2,3,4,4'-tetramethoxy-1,1'-biphenyl: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 165441 |
| CHEMBL ID | 28250 |
| MeSH ID | M0166892 |
| Synonym |
|---|
| mls002608000 , |
| nsc-36768 |
| nsc36768 |
| 6271-59-6 |
| 2,3,4,4'-tetramethoxy-biphenyl |
| CHEMBL28250 , |
| 2,3,4,4''-tetramethoxy-biphenyl |
| bdbm50099947 |
| smr001526756 |
| 1,2,3-trimethoxy-4-(4-methoxyphenyl)benzene |
| HMS3085A15 |
| 2,3,4,4'-tmbp |
| 1,1'-biphenyl, 2,3,4,4'-tetramethoxy- |
| nsc 36768 |
| 2,3,4,4'-tetramethoxy-1,1'-biphenyl |
| TZYDMNYEWNWIMB-UHFFFAOYSA-N |
| 2,3,4,4'-tetramethoxy-1,1'-biphenyl # |
| 1,1'-biphenyl, 4,4',5',6'-tetramethoxy- |
| DTXSID00211795 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.1623 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| TDP1 protein | Homo sapiens (human) | Potency | 9.8773 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| 67.9K protein | Vaccinia virus | Potency | 5.0119 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
| IDH1 | Homo sapiens (human) | Potency | 4.1095 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 44.6684 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 84.9214 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| geminin | Homo sapiens (human) | Potency | 4.1367 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 2.6854 | 0.0580 | 10.6949 | 26.6086 | AID602310; AID651813 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 2.8631 | 0.0259 | 11.2398 | 31.6228 | AID651814; AID651815 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 15.8489 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tubulin polymerization-promoting protein | Bos taurus (cattle) | EC50 (µMol) | 6.2500 | 0.7500 | 3.5000 | 6.2500 | AID1110727 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7 | Homo sapiens (human) | AC50 | 3.9200 | 0.0398 | 15.0025 | 50.0000 | AID743267 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| magnesium ion binding | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| GTPase activity | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| protein binding | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| microtubule binding | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| tubulin binding | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| protein homodimerization activity | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| microtubule | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| nucleus | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| cytoplasm | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| microtubule organizing center | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| perinuclear region of cytoplasm | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| mitotic spindle | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| postsynaptic Golgi apparatus | Tubulin polymerization-promoting protein | Bos taurus (cattle) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1110727 | Inhibition of Bos taurus (bovine) brain tubulin polymerization | 2001 | Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 | Structure-activity relationships of phenylcyclohexene and biphenyl antitubulin compounds against plant and mammalian cells. |
| AID1110725 | Antitumor activity against Homo sapiens (human) HCT116 cells | 2001 | Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 | Structure-activity relationships of phenylcyclohexene and biphenyl antitubulin compounds against plant and mammalian cells. |
| AID1110732 | Inhibition of Nicotiana tabacum (tobacco) root growth assessed as inhibition of root elongation | 2001 | Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 | Structure-activity relationships of phenylcyclohexene and biphenyl antitubulin compounds against plant and mammalian cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.49) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||